CAR-T therapy for refractory ALL wins expert support

An expert panel convened by the FDA has voted unanimously to recommend the approval of a novel immunotherapy that could potentially transform the survival prospects of young people with relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL).   If the FDA accepts its panel’s recommendation, CLT019 will be the first gene therapy to be approved ...

Already a member?

Login to keep reading.

© 2022 the limbic